Royce & Associates LP Acquires 20,230 Shares of Enovis Corporation (NYSE:ENOV)

Royce & Associates LP grew its holdings in Enovis Corporation (NYSE:ENOV - Free Report) by 0.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,490,806 shares of the company's stock after purchasing an additional 20,230 shares during the quarter. Enovis comprises about 1.0% of Royce & Associates LP's investment portfolio, making the stock its 4th largest position. Royce & Associates LP owned 4.36% of Enovis worth $95,174,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Mariner LLC increased its holdings in shares of Enovis by 16.8% in the fourth quarter. Mariner LLC now owns 7,925 shares of the company's stock valued at $348,000 after purchasing an additional 1,142 shares in the last quarter. Comerica Bank lifted its position in Enovis by 22.9% during the 4th quarter. Comerica Bank now owns 49,560 shares of the company's stock valued at $2,175,000 after purchasing an additional 9,224 shares during the period. Vanguard Group Inc. lifted its position in Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after purchasing an additional 75,348 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Enovis during the 4th quarter valued at about $10,970,000. Finally, Southeastern Asset Management Inc. TN lifted its position in Enovis by 60.6% during the 4th quarter. Southeastern Asset Management Inc. TN now owns 36,583 shares of the company's stock valued at $1,605,000 after purchasing an additional 13,797 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.

Analyst Ratings Changes

ENOV has been the subject of a number of analyst reports. JMP Securities lowered their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Needham & Company LLC decreased their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Evercore ISI decreased their price objective on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $55.60.

Enovis Stock Performance

Shares of ENOV stock traded down $0.44 on Thursday, reaching $27.27. The stock had a trading volume of 212,597 shares, compared to its average volume of 1,184,231. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52. The firm's 50-day moving average is $32.03 and its two-hundred day moving average is $36.85. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -1.95 and a beta of 1.70. Enovis Corporation has a 12 month low of $25.93 and a 12 month high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The firm had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. During the same period in the previous year, the business posted $0.50 earnings per share. The company's revenue for the quarter was up 8.2% compared to the same quarter last year. On average, research analysts expect that Enovis Corporation will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.